Warning and Advisories for Healthcare Providers > Letters to Healthcare Providers

Letters to Healthcare Providers   Fingolimod (Gilenya▼): new contraindications in relation to cardiac risk (Letter to Healthcare Professionals)       Attachment: Fingolimod (Gilenya▼): new contraindications in relation to cardiac risk   Related Information: The United Kingdom: Fingolimod (Gilenya▼): new contraindications in relation to ... Posted 2017-12-15 Canada: Gilenya (fingolimod) - Stronger recommendations regarding first-dose car... Posted 2012-08-24 The United States: FDA Drug Safety Communication: Revised recommendations for ca... Posted 2012-05-15 European Union: European Medicines Agency gives new advice to better manage risk... Posted 2012-04-21 Canada: Gilenya (fingolimod) is under review in light of serious adverse events ... Posted 2012-02-28 European Union: European Medicines Agency starts review of Gilenya (fingolimod) ... Posted 2012-01-21